"Texas Oncology is an independent private practice with more than 500 physicians and 210 locations across the state. Meeting the oncology needs of Texans for more than 35 years, the practice includes Texas Center for Proton Therapy, Texas Breast Specialists, Texas Oncology Surgical Specialists, and Texas Center for Interventional Surgery. As a lead participant in US Oncology Research, Texas Oncology played a role in the development of more than 100 FDA-approved therapies."

During the past decade, Texas Oncology Cancer Center conducted 117 clinical trials. In the 10-year time frame, 117 clinical trials started and 72 clinical trials were completed, i.e. on average, 61.5% percent of trials that started reached the finish line to date. In the past 5 years, 58 clinical trials started and 43 clinical trials were completed. i.e. 74.1% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Texas Oncology Cancer Center" #1 sponsor was "Hoffmann-La Roche" with 15 trials, followed by "National Cancer Institute (NCI)" with 10 trials sponsored, "Bristol-Myers Squibb" with 9 trials sponsored, "Eli Lilly and Company" with 8 trials sponsored and "US Oncology Research" with 8 trials sponsored. Other sponsors include 125 different institutions and companies that sponsored additional 83 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Texas Oncology Cancer Center" #1 collaborator was "National Cancer Institute (NCI)" with 13 trials as a collaborator, "NRG Oncology" with 7 trials as a collaborator, "Sanofi" with 5 trials as a collaborator, "Bristol-Myers Squibb" with 4 trials as a collaborator and "Eli Lilly and Company" with 4 trials as a collaborator. Other collaborators include 63 different institutions and companies that were collaborators in the rest 56 trials.

According to Clinical.Site data, the most researched conditions in "Texas Oncology Cancer Center" are "Breast Cancer" (23 trials), "Ovarian Cancer" (12 trials), "Metastatic Breast Cancer" (10 trials), "Multiple Myeloma" (7 trials) and "Prostate Cancer" (7 trials). Many other conditions were trialed in "Texas Oncology Cancer Center" in a lesser frequency.

Most popular intervention types in "Texas Oncology Cancer Center" are "Drug" (165 trials), "Other" (26 trials), "Biological" (19 trials), "Radiation" (15 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Paclitaxel" (19 trials), "Carboplatin" (17 trials), "Laboratory Biomarker Analysis" (13 trials) and "Gemcitabine" (11 trials). Other intervention names were less common.

The vast majority of trials in "Texas Oncology Cancer Center" are 124 trials for "All" genders, 44 trials for "Female" genders and 12 trials for "Male" genders.

Currently, there are NaN active trials in "Texas Oncology Cancer Center". undefined are not yet recruiting, 37 are recruiting, 46 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 71 completed trials in Texas Oncology Cancer Center, 1 suspended trials, and 20 terminated clinical trials to date.

Out of the total trials that were conducted in Texas Oncology Cancer Center, 25 "Phase 1" clinical trials were conducted, 76 "Phase 2" clinical trials and 88 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 3 trials that are defined as “Not Applicable".